Key facts
- This page summarizes Ryan D. Maynard's Form 4 filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Nov 2024, 17:00.
Ryan D. Maynard - 12 Nov 2024 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
- Reporting relationship
- Director
- Issuer ticker
- IOVA
- Reported as of
- 12 Nov 2024
- Net transaction value
- -$130,500
- SEC form
- 4
- Accepted by SEC
- 14 Nov 2024, 17:00:09 UTC
- Prior SEC filing
- 13 Jun 2024
- Next SEC filing
- 17 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ryan Maynard
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ryan D. Maynard filed Form 4 for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) on 14 Nov 2024.
Change
- Previous filing in this sequence was filed on 13 Jun 2024.
- Current net transaction value: -$130,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IOVA
transaction
Common Stock
Options Exercise
- Transaction value
- $372,500
- Shares
- +50,000
- Change %
- +667%
- Price
- $7.45
- Shares after
- 57,500
- Date
- 12 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
IOVA
transaction
Common Stock
Sale
- Transaction value
- $503,000
- Shares
- -50,000
- Change %
- -87%
- Price
- $10.06
- Shares after
- 7,500
- Date
- 12 Nov 2024
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IOVA
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -50,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $7.45
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents an exercise of stock options prior to the 10-year expiration date of such options.
Footnote F2
Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
Footnote F3
Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $10.05 and $10.105.
Footnote F4
These options became exercisable in four equal quarterly installments of 12,500 each following the date of grant, which was February 16, 2015.
Footnote F5
Such aggregate number reflects the remainder of such stock options granted on February 16, 2015, but does not include any other stock options held by such Reporting Person.